Budesonide–formoterol (inhalation powder) in the treatment of COPD

References

• AalbersRAyresJBackerV2002Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trialEur Respir J199364312030736
   PubMed Web of Science ®Google Scholar
• AstraZeneca UK Limited2005Symbicort^® Turbuhaler^® summary of product characteristics [online]Accessed 20 August 2005 URL: http://emc.medicines.org.uk
   Google Scholar
• BalbiBMajoriMBertaccoS2000Inhaled corticosteroids in stable COPD patients: do they have effects on cells and molecular mediators of airway inflammation?Chest1171633710858395
   PubMed Web of Science ®Google Scholar
• BarnesPJ2000aInhaled corticosteroids are not beneficial in chronic obstructive pulmonary diseaseAm J Respir Crit Care Med161342410673166
   PubMed Web of Science ®Google Scholar
• BarnesPJ2000bChronic obstructive pulmonary disease. ReviewN Engl J Med3432698010911010
   PubMed Web of Science ®Google Scholar
• BartowRABrogdenRN1998Formoterol: an update of its pharmacological properties and therapeutic efficacy in the management of asthmaDrugs2303229506248
   PubMed Web of Science ®Google Scholar
• BoobisA1998Comparative physiochemical and pharmacokinetic profiles of inhaled beclomethasone dipropionate and budesonideRespir Med92Suppl B2610193529
   PubMed Web of Science ®Google Scholar
• CalverleyPMBoonsawatZZhongN2003Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J22912914680078
   PubMed Web of Science ®Google Scholar
• CasioMGhezzoHHoggJC1978The relations between structural changes in small airways and pulmonary function testsN Eng J Med298127781
   Web of Science ®Google Scholar
• CazzolaMCentanniSRegordaC2001Onset of action of single doses of formoterol administered via Turbuhaler in patients with stable COPDPulm Pharmacol Ther1441511162418
   PubMed Web of Science ®Google Scholar
• CazzolaMDahlR2004Inhaled combination therapy with long-acting β2-agonists and corticosteroids in stable COPDChest1262203715249466
   PubMed Web of Science ®Google Scholar
• CazzolaMMateraMGSantangeloG1995Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response studyRespir Med89357627638371
   PubMed Web of Science ®Google Scholar
• CazzolaMSantusPDi MarcoF2003Bronchodilator effect of an inhaled combination therapy with salmeterol + fluticasone and formoterol + budesonide in patients with COPDRespir Med97453712735659
   PubMed Web of Science ®Google Scholar
• CazzolaMSantusPDi MarcoF2004Onset of action of formoterol/budesonide in single inhaler vs. formoterol in patients with COPDPulm Pharmacol Ther17121515123220
   PubMed Web of Science ®Google Scholar
• CelikGKayacanOBederS1999Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of actionRespiration66434910516540
   PubMed Web of Science ®Google Scholar
• CheerSMScottLJ2002Formoterol: a review of its use in chronic obstructive pulmonary diseaseAm J Respir Med128530014720051
   PubMedGoogle Scholar
• DahlRKristufekPGreefhorstAPM2000The cardiac safety profile of formoterol dry powder is similar to placebo in patients with COPD [Abstract]Eur Respir J16Suppl 3151sP497
   Google Scholar
• DohertyDE2002Early detection and management of COPD. What you can do to reduce the impact of this disabling diseasePostgrad Med11141412082920
   PubMed Web of Science ®Google Scholar
• DonaldsonGCSeemungalTARBhowmikA2002Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary diseaseThorax578475212324669
   PubMed Web of Science ®Google Scholar
• DonnellyRSealJP2001Clinical pharmacokinetics of inhaled budesonideClin Pharmacokinet404274011475468
   PubMed Web of Science ®Google Scholar
• EdsbäckerS1999Pharmacological factors that influence the choice of inhaled corticosteroidsDrugs58Suppl 4716
   Web of Science ®Google Scholar
• EdsbäckerSBrattsandR2002Budesonide fatty-acid esterification: a novel mechanism prolonging binding to airway tissue. Review of available dataAnn Allergy Asthma Immunol886091612086369
   PubMed Web of Science ®Google Scholar
• FabbriLMHurdSSFor the GOLD Scientific Committee2003Global strategy for the diagnosis, management and prevention of COPDEur Respir J221212882441
   PubMed Web of Science ®Google Scholar
• FauldsDHollingsheadLMGoaKL1991Formoterol. A review of its pharmacological properties and therapeutic potential in reversible obstructive airways diseaseDrugs42115371718682
   PubMed Web of Science ®Google Scholar
• FentonCKeatingGM2004Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary diseaseDrugs6419759615329047
   PubMed Web of Science ®Google Scholar
• GlaxoSmithKline2005Advair Diskus 100/50 250/50 500/50 Prescribing Information [online]Accessed 25 August 2005 URL: http://www.gsk.com/products/advair_us.htm
   Google Scholar
• GizyckiMJHattotuwaKLBarnesN2002Effects of fluticasone propionate on inflammatory cells in COPD: an ultrastructural examination of endobronchial biopsy tissueThorax5779980312200525
   PubMed Web of Science ®Google Scholar
• GoldsmithDRKeatingGM2004Budesonide–formoterol: a review of its use in asthmaDrugs64159761815233594
   PubMed Web of Science ®Google Scholar
• HattotuwaKLGizyckiMJAnsariTW2002The effects of inhaled fluticasone on airway inflammation in chronic obstructive pulmonary disease: a double-blind, placebocontrolled biopsy studyAm J Respir Crit Care Med1651592612070058
   PubMed Web of Science ®Google Scholar
• HvizdosKMJarvisB2000Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disordersDrugs60138
   Web of Science ®Google Scholar
• JohnellOPauwelsRLöfdahlC-G2002Bone mineral density in patient with chronic obstructive pulmonary disease treated with budesonide Turbuhaler®Eur Respir J1910586312108857
   PubMed Web of Science ®Google Scholar
• JohnsonMRennardS2001Alternative mechanisms for long acting β2-adrenergic agonists in COPDChest1202587011451847
   PubMed Web of Science ®Google Scholar
• JonesPWQuirkFHBaveystockCM1992A self-complete measure of health status for chronic airflow limitationAm Rev Respir Dis145132171595997
   PubMed Web of Science ®Google Scholar
• LallooU2002Symbicort®: controlling asthma in adultsRespir Med96Suppl A1622
   Google Scholar
• Llewellyn-JonesCGHillSLStockleyRA1994Effect of fluticasone propionate on neutrophil chemotaxis, superoxide generation, and extracellular proteolytic activity in vitroThorax49207128202875
   PubMed Web of Science ®Google Scholar
• LomasDAIpMChambaA1991The effect of in vitro and in vivo dexamethasone on human neutrophil functionAgents Actions33279851659155
   PubMedGoogle Scholar
• McGavinJKGoaKLJarvisB2001Inhaled budesonide–formoterol combinationDrugs6171811217872
   PubMed Web of Science ®Google Scholar
• NHLBI/WHO2004Global Initiative for Chronic Obstructive Lung DiseaseGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung DiseaseNational Heart, Lung and Blood Institute Update of the management sections [online]Accessed July 2004 URL: http://www.goldcopd.com
   Google Scholar
• OsmanLMGoddenDJFriendJARDouglasJG1997Quality of life and hospital re-admission in patients with chronic obstructive pulmonary diseaseThorax5267719039248
   PubMed Web of Science ®Google Scholar
• PauwelsRABuistASCalverleyPM2001Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) workshop summaryAm J Respir Crit Care Med16312567611316667
   PubMedGoogle Scholar
• PauwelsRALöfdahlCGLaitinenLA1999Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking: European Respiratory Society Study on Chronic Obstructive Pulmonary DiseaseN Engl J Med34019485310379018
   PubMed Web of Science ®Google Scholar
• ReynoldsNAPerryCMKeatingGM2004Budesonide–formoterol in chronic obstructive pulmonary diseaseDrugs644314114969576
   PubMed Web of Science ®Google Scholar
• ScolaAMChongLKSuvamaSK2004Desensitization of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterolBr J Pharmacol1411637114662724
   PubMed Web of Science ®Google Scholar
• SeemungalTARDonaldsonGCPaulEA1998Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary diseaseAm J Respir Crit Care Med1571418229603117
   PubMed Web of Science ®Google Scholar
• SinDDJohnsonMQi GanWPaul ManSF2004Combination therapy of inhaled corticosteroids and long-acting β2-adrenergic in management of patients with chronic obstructive lung diseaseCurr Pharm Des1035476015579052
   PubMed Web of Science ®Google Scholar
• SzafranskiWCukierARamirezA2003Efficacy and safety of budesonide–formoterol in the management of chronic obstructive pulmonary diseaseEur Respir J21748112570112
   PubMed Web of Science ®Google Scholar
• SzeflerSJ1999Pharmacodynamics and pharmacokinetics of budesonide: a new nebulized corticosteroidJ Allergy Clin Immunol104S17583
   PubMed Web of Science ®Google Scholar
• ThorssonLEdsbäckerSConradsonT-B1994Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDIEur Respir J71839447828694
   PubMed Web of Science ®Google Scholar
• XieQMChenJQShenWH2003Comparison of bronchodilating and antiinflammatory activities of oral formoterol and its (R,R)-enantiomerslActa Pharmacol Sin242778212617779
   PubMed Web of Science ®Google Scholar
• YildizFBasyigitIYildirimE2004Does addition of inhaled steroid to combined bronchodilator therapy affect health status in patients with COPD?Respirology9352515363007
   PubMed Web of Science ®Google Scholar